Lone Pine Capital’s Amicus Therapeutics FOLD Stock Holding History

Lone Pine Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,678,788	Closed	-$154M	–	42
2020 Q4	$154M	Buy	+6,678,788	New	+$137M	0.56%	35

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lone Pine Capital's FOLD Position: Q1 2021 in Review

Lone Pine Capital sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 6,678,788 shares — an estimated $154M sold.

Lone Pine Capital first reported a position in FOLD in Q4 2020 and held it in 1 quarter. The position peaked at $154M in Q4 2020. 258 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

Lone Pine Capital reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
Lone Pine Capital sold 6,678,788 Amicus Therapeutics shares in Q1 2021, an estimated $154M.
Lone Pine Capital first reported a position in Amicus Therapeutics in Q4 2020 and held it in 1 quarter.
Lone Pine Capital's Amicus Therapeutics position peaked at $154M in Q4 2020.
258 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Lone Pine Capital's 13F filing for Q1 2021, filed 18 May 2021.